Jing-Zhou Hou, MD, PhD, is a clinical hematological oncologist specialized in hematological malignancies, cell therapy, and bone marrow transplant at UPMC Hillman Cancer Center. He has received many awards, including the Leo Criep, MD Excellence in Patient Care Award at UPMC Hillman Cancer Centers, and has been named to the Castle Connolly Top Doctors list and the Pittsburgh Magazine.



Dr. Hou is a clinical investigator focusing on lymphoma and acute myeloid leukemia (AML). He has been conducting many cutting-edge clinical trials involving bispecific T-cell engagers, immunological and targeted therapies. Many of these trials have led to FDA approvals of the investigational agents such as venetoclax, ibrutinib, acalbrutinib and polatuzumab. Dr. Hou had been a medical consultant/advisor for many pharmaceutical companies including early startup.



Dr. Hou had served as the chair of clinical lymphoma pathway committee in the Clinical Path Oncology from 2010-2015. He continues serving as a voting member of the lymphoma committee since 2009. As a clinical educator, Dr Hou has lectured fellows and residents on management of lymphomas and chronic lymphocytic leukemia (CLL) since 2010. And he is frequently invited to speak at regional, national, and international conferences on the topics of lymphomas and AML.



Dr. Hou received his medical degree from Henan Medical University in China, his master’s degree at Shanghai Medical University, and his PhD in Molecular and Cell Biology from Tulane University. He completed his internal medicine residency in Northeastern Ohio University College of Medicine, and fellowship in Hematology and Oncology at Stanford University. He joined UPMC Hillman Cancer Center in 2007.